These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24976973)

  • 1. Unresectable stage III non-small cell lung cancer: is Tecemotide a new START for our patients?
    Wauters E; Vansteenkiste J
    J Thorac Dis; 2014 Jun; 6(6):574-7. PubMed ID: 24976973
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
    Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.
    DeGregorio M; Soe L; Wolf M
    J Thorac Dis; 2014 Jun; 6(6):571-3. PubMed ID: 24976972
    [No Abstract]   [Full Text] [Related]  

  • 6. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
    Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
    Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model.
    Kao CJ; Wurz GT; Monjazeb AM; Vang DP; Cadman TB; Griffey SM; Wolf M; DeGregorio MW
    Cancer Immunol Res; 2014 Jun; 2(6):581-9. PubMed ID: 24894093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.
    Kao CJ; Wurz GT; Schröder A; Wolf M; Degregorio MW
    Oncoimmunology; 2013 Oct; 2(10):e26285. PubMed ID: 24498545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
    Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
    Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
    Singer CF; Pfeiler G; Hubalek M; Bartsch R; Stöger H; Pichler A; Petru E; Bjelic-Radisic V; Greil R; Rudas M; Maria Tea MK; Wette V; Petzer AL; Sevelda P; Egle D; Dubsky PC; Filipits M; Fitzal F; Exner R; Jakesz R; Balic M; Tinchon C; Bago-Horvath Z; Frantal S; Gnant M;
    Eur J Cancer; 2020 Jun; 132():43-52. PubMed ID: 32325419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer.
    Suzuki S; Goto T
    J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33260352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of immunotherapy in stage III nonsmall cell lung cancer.
    Wrona A
    Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance and consolidation therapy in patients with unresectable stage III/IV non-small cell lung cancer.
    Thatcher N; Heighway J
    Oncologist; 2010; 15(10):1034-42. PubMed ID: 20930098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review.
    Lesueur P; Martel-Laffay I; Escande A; Kissel M; Locher C; Gervais R; Schott R; Vergnenegre A; Chouaid C
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1159-1165. PubMed ID: 30173589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
    Takase N; Hattori Y; Kiriu T; Itoh S; Kawa Y; Yamamoto M; Urata Y; Shimada T; Tsujino K; Soejima T; Negoro S; Satouchi M
    Respir Investig; 2016 Sep; 54(5):334-40. PubMed ID: 27566381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
    Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
    Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study.
    Nichols RC; Huh SN; Henderson RH; Mendenhall NP; Flampouri S; Li Z; D'Agostino HJ; Cury JD; Pham DC; Hoppe BS
    Clin Lung Cancer; 2011 Jul; 12(4):252-7. PubMed ID: 21726825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party.
    Sculier JP; Paesmans M; Ninane V; Giner V; Bureau G; Lafitte JJ; Baumöhl J; Thiriaux J; van Cutsem O; Recloux P; Berchier MC; Zacharias C; Mommen P; van Houtte P; Klastersky J
    Lung Cancer; 1998 Dec; 22(3):201-13. PubMed ID: 10048473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.